Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.76 |
| ▸ | IL1RN | P18510 | 8/20 | 0.63 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.63 |
| ▸ | ECE1 | P42892 | 5/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839328 | 0.96 | ERAP2 (0.73) | ERAP2IL1RNERAP1ECE1ACE | |
| SCHEMBL20764526 | 0.96 | ERAP2 (0.70) | ERAP2IL1RNERAP1ECE1ACE | |
| SCHEMBL29815684 | 0.94 | ERAP2 (0.76) | ERAP2IL1RNERAP1ECE1ACE | |
| SCHEMBL29376316 | 0.94 | ERAP2 (0.67) | ERAP2IL1RNERAP1ECE1ACE | |
| SCHEMBL31720529 | 0.93 | ERAP2 (0.74) | ERAP2IL1RNERAP1ECE1ACE | |
| SCHEMBL30465848 | 0.93 | ERAP2 (0.71) | ERAP2IL1RNERAP1ECE1 | |
| SCHEMBL29538468 | 0.92 | ERAP2 (0.69) | ERAP2IL1RNERAP1ECE1ACE | |
| SCHEMBL3547828 | 0.92 | KDM4E (0.64) | ERAP2ECE1ACE | |
| SCHEMBL3547835 | 0.92 | KDM4E (0.64) | ERAP2ECE1ACE | |
| SCHEMBL29405435 | 0.92 | KDM4E (0.64) | ERAP2ECE1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230085176-A1 | PEPTIDE-BASED INHIBITORS OF GROWTH HORMONE ACTION AND METHODS OF USE THEREOF | OHIO UNIVERSITY (US) | 2023-03-16 | — | — | US | claimed |
| CN-117003803-B | Crystal form of trisaccharide | Hengrui (Qingdao) Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-114080232-B | Extracellular vesicles for vaccine delivery | Lhasa Sales Co.,Ltd. (CH) | 2026-05-26 | — | — | CN | disclosed |
| CN-116583298-B | PD-1 targeted IL-15/IL-15RαFC fusion proteins with improved properties | 基因泰克公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12618082-B2 | Engineered muscle targeting compositions | THE BROAD INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4689177-A1 | NOVEL METHOD FOR ISOTHERMAL AMPLIFICATION OF PADLOCK PROBES FOR NUCLEIC ACID DETECTION AND PHI29 DNA POLYMERASE VARIANTS | Consejo Superior De Investigaciones Científicas (ES) | 2026-02-11 | — | — | EP | disclosed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250277052-A1 | MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2 AND CD63 | VASCULAR BIOGENICS LTD. (IL) | 2025-09-04 | — | — | US | disclosed |
| US-20250269065-A1 | B-CELL LYMPHOMA 2-ASSOCIATED ANTHANOGENE 3 (BAG3) GENE THERAPY USING AAV VECTOR | SPACECRAFT SEVEN, LLC (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025128817-A1 | ARTIFICIAL MICRORNAS TARGETING TAU | GENZYME CORPORATION (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-114008197-A | Metabolic engineering for simultaneous consumption of xylose and glucose to produce chemicals from second generation sugars | 布拉斯科公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008069-A | Compositions of exosomes and AAV | 科迪亚克生物科学公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-112592912-B | Glycosidase, encoding gene thereof and application thereof | 云南与诺生物工程有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008207-A | Improved gene editing system | 中国科学院遗传与发育生物学研究所 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008070-A | Whole genome rationally designed mutations leading to increased lysine production in E.coli | 因思科瑞普特公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993989-A | Process for producing ergothioneine | 丹麦科技大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993552-A | Adeno-associated virus vector formulations and methods | 再生生物股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2022020616-A1 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| CN-113969268-A | Glu/Leu/Phe/Val dehydrogenase mutant and application thereof in preparation of L-glufosinate-ammonium | 永农生物科学有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113969269-A | D-amino acid oxidase mutant and application thereof in preparation of L-glufosinate-ammonium | 永农生物科学有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618082-B2 | Engineered muscle targeting compositions | MUSK, MYO3B, MYOF | ERAP2 1244/4885IL1RN 1603/4885ERAP1 775/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | ERAP2 257/4885IL1RN 1190/4885ERAP1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.